PMID: 12760308May 23, 2003Paper

Steroid and xenobiotic receptor (SXR) is a key system for the acquisition of cisplatin resistance in endometrial cancer cells

The Journal of International Medical Research
N TakamiT Yamamoto

Abstract

A novel steroid and xenobiotic receptor (SXR) may be involved in chemoresistance, and we studied this receptor in endometrial cancer cell lines. The cisplatin (CDDP)-sensitive Ishikawa cell line and its CDDP-resistant sub-clone (ISIW+) were used. ISIW+ cells showed a much higher SXR expression. When Ishikawa cells were cultured with SXR anti-sense oligonucleotides (AS), the cells failed to pass crisis and did not gain cisplatin resistance. In an experiment using SCID mice, all AS-treated animals survived, whereas controls had 50% survival at 35 days. The present data indicate that SXR is a key system to induce, maintain and reverse a cisplatin-resistant phenotype in endometrial cancer cells.

References

Sep 1, 1995·Current Opinion in Oncology·J B Vermorken, K Hoekman
Aug 5, 2000·Pathology, Research and Practice·D MayrJ Diebold
Dec 1, 2001·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·S GotoT Kondo
Sep 10, 2002·The Lancet Oncology·Mark Harries, Martin Gore
Sep 10, 2002·The Lancet Oncology·Mark Harries, Martin Gore

❮ Previous
Next ❯

Citations

Dec 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M Michael, M M Doherty
Apr 20, 2013·Oncology Letters·Enqi QiaoJinhai Tang
May 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sanjay GoelSridhar Mani
Sep 8, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sridhar ManiSusan B Horwitz
Dec 13, 2007·Molecular Pharmaceutics·Shirley Teng, Micheline Piquette-Miller

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.